Patient main baseline characteristics
| Characteristics . | RCT arm A (dapsone), n = 46 . | RCT arm B (control) group), n = 47 . | Observational study cohort (dapsone), n = 46 . |
|---|---|---|---|
| Age at ITP diagnosis, median (range), y | 48 (30-65) | 49 (30-62) | 51 (29-72) |
| Women, n (%) | 26 (57) | 25 (53) | 24 (52) |
| Platelet count at diagnosis, median, ×109/L (range) | 13 (7-32) | 11.5 (7-32) | 10.0 (5.0-23.0) |
| ITP duration, median (range), y | 0.27 (0.16-0.92) | 0.23 (0.15-0.92) | 0.22 (0.041-6.06)∗ |
| Bleeding symptoms at diagnosis, n (%) | 22 (49) | 24 (51) | 36 (78) |
| Previous treatment with corticosteroids, n (%) | 44 (96) | 47 (100) | 46 (100) |
| Previous treatment with IVIg, n (%) | 17 (37) | 18 (38) | 18 (39) |
| Characteristics . | RCT arm A (dapsone), n = 46 . | RCT arm B (control) group), n = 47 . | Observational study cohort (dapsone), n = 46 . |
|---|---|---|---|
| Age at ITP diagnosis, median (range), y | 48 (30-65) | 49 (30-62) | 51 (29-72) |
| Women, n (%) | 26 (57) | 25 (53) | 24 (52) |
| Platelet count at diagnosis, median, ×109/L (range) | 13 (7-32) | 11.5 (7-32) | 10.0 (5.0-23.0) |
| ITP duration, median (range), y | 0.27 (0.16-0.92) | 0.23 (0.15-0.92) | 0.22 (0.041-6.06)∗ |
| Bleeding symptoms at diagnosis, n (%) | 22 (49) | 24 (51) | 36 (78) |
| Previous treatment with corticosteroids, n (%) | 44 (96) | 47 (100) | 46 (100) |
| Previous treatment with IVIg, n (%) | 17 (37) | 18 (38) | 18 (39) |
1 missing data.